文献速递慢性肾脏病遗传性与小管间质肾病

联合胱抑素C与肌酐可提高ADPKD中eGFR斜率准确性

Combining Cystatin C and Creatinine Increases eGFR Slope Accuracy in ADPKD.
PubMed 文献 · Kidney Int Rep · 2026-08-06

在260例常染色体显性多囊肾病(ADPKD)患者中,比较常规eGFRcr、批测eGFRcr、eGFRcys及eGFRcr-cys与碘他拉酸盐测定的mGFR。结果显示eGFRcr-cys斜率与mGFR下降相关性更强(CCC 0.68 vs 0.58,P=0.02),斜率变异性降低可使临床试验样本量减少37%至38%。

要点

  • eGFRcr-cys斜率与mGFR下降相关性优于eGFRcr(CCC 0.68 vs 0.58,P=0.02)。
  • eGFRcr-cys斜率标准差低于eGFRcr和eGFRcys,变异性更小。
  • 斜率变异性降低可使ADPKD临床试验样本量减少37%至38%。

核心结论

  • 使用eGFRcr-cys可提高精度并降低eGFR斜率变异性,可能优化ADPKD试验效率与设计。

研究设计与样本

  • DIPAK观察性队列中260例ADPKD患者,比较2021 CKD-EPI公式基于常规临床肌酐、批测肌酐、批测胱抑素C及两者联合的eGFR与mGFR。

主要发现

  • 横断面性能:批测eGFRcr与常规eGFRcr大致相似;eGFRcys和eGFRcr-cys偏倚大于eGFRcr;eGFRcr-cys精度最高。
  • 纵向:批测eGFRcr-cys斜率与mGFR下降的CCC为0.68(95%CI 0.59-0.76),eGFRcr为0.58(95%CI 0.47-0.67),P=0.02。
  • eGFRcr-cys斜率标准差低于eGFRcr和eGFRcys,使临床试验样本量减少37%至38%。

关键数值与推荐

  • eGFRcr-cys斜率与mGFR下降的CCC为0.68(95%CI 0.59-0.76),eGFRcr为0.58(95%CI 0.47-0.67),P=0.02。
  • eGFRcr-cys斜率变异性降低使临床试验样本量减少37%至38%。

临床怎么用

  • 在ADPKD临床试验中可考虑采用eGFRcr-cys作为终点指标以提高精度并减少样本量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: In autosomal dominant polycystic kidney disease (ADPKD) trials, creatinine-based estimated glomerular filtration rate (GFR, eGFRcr) is a key end point; however, variability in creatinine measurements may affect reliability. We compared routine eGFRcr to eGFR derived from batch-measured creatinine, cystatin C (eGFRcys), or both (eGFRcr-cys) using biobanked samples, against iothalamate-measured GFR (mGFR). METHODS: In the 260 patients with ADPKD from the DIPAK observational cohort, we compared 2021 Chronic Kidney Disease (CKD)-Epidemiology Collaboration (CKD-EPI)-based eGFR based on the following: (i) routine clinical creatinine, (ii) batch-measured creatinine, and (iii) batch-measured cystatin C to mGFR. Creatinine and cystatin batch measurements were performed on the same day to minimize variability. Cross-sectional performance was evaluated by bias (eGFR - mGFR), precision, accuracy (P30/P10), and CKD stage agreement. Longitudinal agreement between mGFR and eGFR slopes (ml/min per 1.73 m2/yr) was assessed using concordance correlation coefficients (CCC). Sample size requirements for hypothetical trials were calculated based on slope variability. RESULTS: Cross-sectional performance of batch-measured eGFRcr was largely similar to routine eGFRcr. eGFRcys and eGFRcr-cys showed greater bias than eGFRcr; eGFRcr-cys showed the highest precision. Longitudinally, batch-measured eGFRcr-cys slopes correlated more strongly with mGFR decline than eGFRcr (CCC: 0.68; 95% confidence interval [CI]: 0.59-0.76] vs. 0.58 [95% CI: 0.47-0.67]; P = 0.02). eGFRcr-cys slopes exhibited lower SDs than eGFRcr and eGFRcys. This reduction in slope variability translated to sample size reductions of 37% to 38% for clinical trials. CONCLUSION: The use of eGFRcr-cys enhances precision and reduces eGFR slope variability. Using combined creatinine-cystatin C estimates may optimize trial efficiency and design in ADPKD.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Bais T, Mohamed AAA, Noruzi A, et al. Combining Cystatin C and Creatinine Increases eGFR Slope Accuracy in ADPKD. Kidney Int Rep. 2026. PMID: 42733501. doi:10.1016/j.ekir.2026.107008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。